AIA Group Ltd Trims Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AIA Group Ltd decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,848 shares of the biopharmaceutical company's stock after selling 5,369 shares during the quarter. AIA Group Ltd's holdings in Alnylam Pharmaceuticals were worth $5,376,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Quantbot Technologies LP lifted its stake in Alnylam Pharmaceuticals by 1,754.5% during the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 193 shares in the last quarter. Bridgewater Associates LP acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $551,000. Captrust Financial Advisors lifted its stake in Alnylam Pharmaceuticals by 34.4% during the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company's stock worth $1,329,000 after purchasing an additional 1,237 shares during the last quarter. True Wealth Design LLC lifted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 153 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $4,539,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALNY. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. HC Wainwright reiterated a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Finally, Scotiabank lifted their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $316.25.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $26.42 during trading hours on Friday, hitting $235.74. 1,881,579 shares of the stock were exchanged, compared to its average volume of 842,696. The company's fifty day simple moving average is $259.03 and its two-hundred day simple moving average is $260.33. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a market cap of $30.67 billion, a PE ratio of -108.64 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.